Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-056072

PhaseBio Pharmaceuticals Inc · PHAS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
David M Mott
10% Owner
Period of report
Oct 22, 2018
Accepted (ET)
Oct 24, 2018 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169245

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Oct 22, 2018C4,841,634—A4,841,634ISee Note 2
Common StockF2Oct 22, 2018P1,800,000$5.00A6,641,634ISee Note 2

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Warrants to Purchase Series B Preferred StockF2,F4$0.12Oct 22, 2018X49,030D——Series B Preferred Stock49,0300I
Series B Preferred StockF2,F1—Oct 22, 2018X49,030A——Common Stock49,0303,280,804I
Series B Preferred StockF2,F1—Oct 22, 2018S1,177D——Common Stock1,1773,279,627I
Series B Preferred StockF2,F1—Oct 22, 2018C3,279,627D——Common Stock3,279,6270I
Warrants to Purchase Series C-1 Preferred StockF2,F4$0.12Oct 22, 2018X181,190D——Series C-1 Preferred Stock181,1900I
Series C-1 Preferred StockF2,F1—Oct 22, 2018X181,190A——Common Stock181,190442,055I
Series C-1 Preferred StockF2,F1—Oct 22, 2018S4,349D——Common Stock4,349437,706I
Series C-1 Preferred StockF2,F1—Oct 22, 2018C437,706D——Common Stock437,7060I
Series D Preferred StockF2,F1—Oct 22, 2018C1,124,301D——Common Stock1,124,3010I

Explanation of responses